Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;31(6):1823-1830.
doi: 10.1111/odi.15232. Epub 2024 Dec 30.

Interaction Between Sclerostin and Mast Cells in Fibro-Osseous Lesions of the Jaws

Affiliations

Interaction Between Sclerostin and Mast Cells in Fibro-Osseous Lesions of the Jaws

Riéli Elis Schulz et al. Oral Dis. 2025 Jun.

Abstract

Objective: To assess the sclerostin, β-catenin, and tryptase expression in fibro-osseous lesions (FOL) of the jaws.

Subjects and methods: Immunohistochemistry analysis was performed for these proteins on FOL and non-lesional bone. The sclerostin-positive cells were scored from 0 (no expression) to 3 (high expression).

Results: We analyzed 46 FOL biopsies and selected 38 patients. Categorization showed 15 fibrous dysplasia (FD), eight juvenile trabecular ossifying fibroma (JTOF), two psammomatoid ossifying fibroma (PsOF), and 13 FOL. We found more sclerostin-positive cells in fibrous tissue than in bone, showing a phenotype like mast cells with strong dot-cytoplasmic positivity. The analysis of sclerostin-positive cell lesions (scored as 2 and 3) showed also tryptase positivity in 80.9% of 21 biopsies. β-catenin was diffusely expressed on the fibrous component, mostly with cytosol staining. Non-lesional bone showed sclerostin expression in medullary spaces and a few osteocytes.

Conclusions: Sclerostin-positive cells are mostly found in the fibrous tissue of FOL, and the tryptase mast cell marker was present in most of the lesions that were positive for sclerostin.

Keywords: SOST protein; bone diseases; bone fibrous dysplasia; developmental; human; mast cells; ossifying fibroma.

PubMed Disclaimer

References

    1. Akers, I. A., M. Parsons, M. R. Hill, et al. 2000. “Mast Cell Tryptase Stimulates Human Lung Fibroblast Proliferation via Protease‐Activated Receptor‐2.” American Journal of Physiology. Lung Cellular and Molecular Physiology 278, no. 1: L193–L201.
    1. Bellido, T. 2014. “Osteocyte‐driven bone remodeling.” Calcified Tissue International 94: 25–34.
    1. Diolintzi, A., M. S. Pervin, and E. C. Hsiao. 2024. “Immunologic Aspects in Fibrodysplasia Ossificans Progressiva.” Biomolecules 14, no. 3: 357.
    1. Dreyer, T. J., J. A. Keen, L. M. Wells, and S. J. Roberts. 2023. “Novel Insights on the Effect of Sclerostin on Bone and Other Organs.” Journal of Endocrinology 257, no. 2: e220209.
    1. Fischer, V., and M. Haffner‐Luntzer. 2022. “Interaction Between Bone and Immune Cells: Implications for Postmenopausal Osteoporosis.” Seminars in Cell & Developmental Biology 123: 14–21.

MeSH terms

LinkOut - more resources